SUNNYVALE, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ:ISRG), a global technology
leader in robotic-assisted, minimally invasive surgery, today announced certain unaudited preliminary fourth quarter and full year
2017 financial results ahead of its participation at the 36th Annual JP Morgan Healthcare Conference on January 10-11, 2018, in San
Francisco, California.
Q4 and 2017 Highlights
- Fourth quarter 2017 worldwide da Vinci procedures increased approximately 17% compared with the fourth quarter
of 2016. Full year 2017 worldwide da Vinci procedures increased approximately 16% compared with
2016.
- Preliminary fourth quarter 2017 revenue of $892 million grew approximately 18% compared with $757 million
for the fourth quarter of 2016. Preliminary 2017 revenue of $3.1 billion grew approximately 16% compared
with $2.7 billion for 2016.
- The Company shipped 216 da Vinci Surgical Systems compared with 163 in
the fourth quarter of 2016. The Company shipped 684 da Vinci Surgical Systems in 2017, compared with
537 systems in 2016.
- In December 2017, the Company filed form 510(k)s with the U.S. Food and Drug Administration for the da Vinci Single
Port Surgical System for use in certain urology procedures and a 60mm version of the da Vinci Xi stapler.
Preliminary Results
The Company expects revenue for the fourth quarter of 2017 of approximately $892 million, an increase of
approximately 18% compared with $757 million for the fourth quarter of 2016. The Company expects 2017 revenue of approximately $3.1
billion, an increase of approximately 16% compared with $2.7 billion for 2016. These unaudited results are preliminary and prior to
the completion of the Company’s annual independent audit and therefore are subject to adjustment.
Preliminary fourth quarter 2017 instrument and accessory revenue increased approximately 18% to approximately
$457 million compared with $386 million for the fourth quarter of 2016. Full year 2017 instrument and accessory revenue increased
approximately 17% to approximately $1.6 billion. Fourth quarter and full year 2017 instrument and accessory revenue growth was
driven primarily by da Vinci procedure growth.
da Vinci procedures increased approximately 17% for the fourth quarter of 2017 compared with the
fourth quarter of 2016. Approximately 877,000 surgical procedures were performed with the da Vinci Surgical System in
2017, an increase of approximately 16% compared with approximately 753,000 procedures performed in 2016. The growth in overall 2017
procedure volume was primarily driven by the growth in U.S. general surgery procedures and worldwide urologic procedures. The
Company expects total da Vinci procedures to grow approximately 11% to 15% in 2018.
Preliminary fourth quarter 2017 da Vinci Surgical Systems revenue increased approximately 20%
to approximately $283 million from $236 million for the fourth quarter of 2016. Systems revenue for 2017 increased approximately
15% to approximately $910 million compared with $792 million in 2016. The Company shipped 216 da Vinci Surgical
Systems in the fourth quarter of 2017, compared with 163 systems in the fourth quarter of 2016. The fourth quarter 2017 da
Vinci Surgical Systems shipments included 40 shipped under operating lease arrangements, compared with 13 in the fourth
quarter of 2016. The Company shipped 684 da Vinci Surgical Systems in 2017, compared with 537 systems in
2016.
Preliminary fourth quarter 2017 service revenue of approximately $153 million increased approximately 13%
compared with $135 million in the fourth quarter of 2016. Preliminary 2017 service revenue increased approximately 13% to
approximately $582 million compared with $517 million in 2016.
Commenting on the announcement, Dr. Gary Guthart, President and CEO of Intuitive Surgical, said, “We are pleased
with the progress our team made in supporting our customers in 2017. In 2018, we will continue to invest in the new technologies
and services that are important to surgeons, patients and hospitals, and core to our mission.”
Additional unaudited preliminary revenue and procedure information has been posted to the Investor Relations
section of the Intuitive Surgical website at: http://phx.corporate-ir.net/phoenix.zhtml?c=122359&p=irol-IRHome.
The Company is scheduled to present at the 2018 JP Morgan Healthcare Conference on January 11, 2018, at 9:00
a.m. Pacific Time. The Company is scheduled to report its fourth quarter 2017 results during a conference call on January 25,
2018, at which point the Company will discuss the 2017 financial results in more detail. Dial-in and webcast access information for
both of these events are also available in the Investor Relations section of the Intuitive Surgical website.
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global technology
leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures, and markets robotic
technologies designed to improve clinical outcomes and help patients return more quickly to active and productive lives. The
Company’s mission is to extend the benefits of minimally invasive surgery to the broadest possible base of patients. Intuitive
Surgical - Taking surgery beyond the limits of the human hand™.
About the da Vinci Surgical System
The da Vinci Surgical System is a surgical platform designed to enable complex surgery using
a minimally invasive approach. The da Vinci Surgical System consists of an ergonomic surgeon console or
consoles, a patient-side cart with three or four interactive arms, a high-performance vision system and
proprietary EndoWrist instruments. Powered by state-of-the-art technology, the da
Vinci Surgical System is designed to scale, filter, and seamlessly translate the surgeon’s hand movements into more
precise movements of the EndoWrist instruments. The net result is an intuitive interface with improved surgical
capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision, and ergonomic comfort,
the da Vinci Surgical System makes it possible for skilled surgeons to perform more minimally invasive
procedures involving complex dissection or reconstruction. Surgeons, hospitals, and patients benefit from a large community of
users and the Company’s robotic-assisted surgical ecosystem, beginning with the robotic platforms, and also including the broad
instrument product line, imaging solutions, training programs and technology, clinical validation, field clinical support, field
technical support, and program optimization. For more information about clinical evidence related to da
Vinci Surgery, please visit https://www.intuitivesurgical.com/company/clinical-evidence/.
da Vinci® and EndoWrist® are trademarks of Intuitive Surgical, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the Company’s unaudited
preliminary financial and operational results for the fourth quarter and full year 2017, expected procedure growth in 2018, and
investment in new technologies and services 2018. These forward-looking statements are necessarily estimates reflecting the best
judgment of management and involve a number of risks and uncertainties that could cause actual results to differ materially from
those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of
various important factors, including, but not limited to, the following: completion of the Company’s final closing procedures,
final adjustments and other developments that may arise in the course of audit procedures; the impact of global and regional
economic and credit market conditions on healthcare spending; healthcare reform legislation in the United States and its impact on
hospital spending, reimbursement and fees levied on certain medical device revenues; changes in hospital admissions and actions by
payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed
products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships;
procedure counts; regulatory approvals, clearances and restrictions or any dispute that may occur with any regulatory body;
guidelines and recommendations in the healthcare and patient communities; intellectual property positions and litigation;
competition in the medical device industry and in the specific markets of surgery in which the Company operates; unanticipated
manufacturing disruptions or the inability to meet demand for products; the results of legal proceedings to which the Company is or
may become a party; product liability and other litigation claims; adverse publicity regarding the Company and the safety of its
products and adequacy of training; the Company's ability to expand into foreign markets; and other risk factors under the heading
“Risk Factors” in the Company's report on Form 10-K for the year ended December 31, 2016, as updated by its other filings with the
Securities and Exchange Commission. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,”
“expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted” and similar words and expressions are intended to
identify forward-looking statements. You are cautioned not to place undue reliance on these forward looking statements, which speak
only as of the date of this press release. The Company undertakes no obligation to publicly update or release any revisions to
these forward-looking statements, except as required by law.
Contact: Investor Relations
(408) 523-2161
